{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidfrhv7hr7pamvfket3mkccffv2xzklk7vceht7stzhxzccykyjx4",
    "uri": "at://did:plc:o7x3aaueo7gbdj5s6ywwl7sl/app.bsky.feed.post/3mkchj5a6vw62"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihgi6h2f6zlnhtp2h5pp6kucgjsojlsez6sx7csgnkugjqk5bs5oa"
    },
    "mimeType": "image/png",
    "size": 333756
  },
  "path": "/trump-regeneron-drug-price-deal/?utm_source=rss&utm_medium=rss&utm_campaign=trump-regeneron-drug-price-deal",
  "publishedAt": "2026-04-24T17:15:21.000Z",
  "site": "https://thedeepdive.ca",
  "tags": [
    "Healthcare",
    "Latest",
    "Donald Trump",
    "drug prices",
    "Regeneron",
    "The Fine Print In Trump’s Most-Favored-Nation Drug Price Deal With Regeneron",
    "the deep dive"
  ],
  "textContent": "President Donald Trump’s most-favored-nation drug pricing campaign reached its biggest political milestone after Regeneron Pharmaceuticals became the final company among 17 major drugmakers targeted by the White House to strike a pricing deal. The agreement requires Regeneron to lower Medicaid prices based on prices in other developed countries, align US prices for future medicines with […]\n\nThe post The Fine Print In Trump’s Most-Favored-Nation Drug Price Deal With Regeneron appeared first on the deep dive.",
  "title": "The Fine Print In Trump’s Most-Favored-Nation Drug Price Deal With Regeneron"
}